FDA clears safety test to screen Tysabri patients
WASHINGTON — The Food and Drug Administration says it has standard a novel diagnostic test to help identify patients who receive an increased chance of upward a rare intellect infection while taking Biogen Idecs multiple sclerosis drug Tysabri.Tysabri is lone of a handful of drugs used to control multiple sclerosis, a devastating disease wearing which the body attacks its own worried orderliness. Prescribing of the drug has been tightly controlled by the FDA since of a rare elevation effect with the aim of causes fatal inflammation of the reason.The newly agreed Stratify JCV test is designed to detect a widespread virus so as to increases patients odds of increasing the wits infection. The virus is harmless during for the most part patients, but can suit hazardous during patients taking immune system-suppressing drugs like Tysabri.
.